| dc.contributor.author | Yip, K | |
| dc.contributor.author | Melcher, A | |
| dc.contributor.author | Harrington, K | |
| dc.contributor.author | Illidge, T | |
| dc.contributor.author | Nobes, J | |
| dc.contributor.author | Webster, A | |
| dc.contributor.author | Smith, D | |
| dc.contributor.author | Lorigan, P | |
| dc.contributor.author | Nathan, P | |
| dc.contributor.author | Larkin, J | |
| dc.date.accessioned | 2018-04-27T10:14:08Z | |
| dc.date.issued | 2018-04 | |
| dc.identifier.citation | Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (4), pp. 201 - 203 | |
| dc.identifier.issn | 0936-6555 | |
| dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/1657 | |
| dc.identifier.eissn | 1433-2981 | |
| dc.identifier.doi | 10.1016/j.clon.2018.01.001 | |
| dc.format | Print | |
| dc.format.extent | 201 - 203 | |
| dc.language | eng | |
| dc.language.iso | eng | |
| dc.rights.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| dc.title | Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. | |
| dc.type | Journal Article | |
| dcterms.dateAccepted | 2017-12-14 | |
| rioxxterms.versionofrecord | 10.1016/j.clon.2018.01.001 | |
| rioxxterms.licenseref.uri | https://www.rioxx.net/licenses/under-embargo-all-rights-reserved | |
| rioxxterms.licenseref.startdate | 2018-04 | |
| rioxxterms.type | Journal Article/Review | |
| dc.relation.isPartOf | Clinical oncology (Royal College of Radiologists (Great Britain)) | |
| pubs.issue | 4 | |
| pubs.notes | Not known | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.organisational-group | /ICR | |
| pubs.organisational-group | /ICR/Primary Group | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.) | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy | |
| pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Immunotherapy/Translational Immunotherapy (TL) | |
| pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
| pubs.publication-status | Published | |
| pubs.volume | 30 | |
| pubs.embargo.terms | Not known | |
| icr.researchteam | Melanoma and Kidney Cancer | en_US |
| icr.researchteam | Targeted Therapy | en_US |
| icr.researchteam | Translational Immunotherapy | en_US |
| dc.contributor.icrauthor | Harrington, Kevin | |
| dc.contributor.icrauthor | Melcher, Alan | |
| dc.contributor.icrauthor | Larkin, James | |
